Human cancer cell lines are the workhorse of cancer research. Although cell lines are known to evolve in culture, the extent of the resultant genetic and transcriptional heterogeneity and its functional consequences remain understudied. Here we use genomic analyses of 106 human cell lines grown in two laboratories to show extensive clonal diversity. Further comprehensive genomic characterization of 27 strains of the common breast cancer cell line MCF7 uncovered rapid genetic diversification. Similar results were obtained with multiple strains of 13 additional cell lines. Notably, genetic changes were associated with differential activation of gene expression programs and marked differences in cell morphology and proliferation. Barcoding experiments showed that cell line evolution occurs as a result of positive clonal selection that is highly sensitive to culture conditions. Analyses of single-cell-derived clones demonstrated that continuous instability quickly translates into heterogeneity of the cell line. When the 27 MCF7 strains were tested against 321 anti-cancer compounds, we uncovered considerably different drug responses: at least 75% of compounds that strongly inhibited some strains were completely inactive in others. This study documents the extent, origins and consequences of genetic variation within cell lines, and provides a framework for researchers to measure such variation in efforts to support maximally reproducible cancer research.
Human cancer cell lines have facilitated fundamental discoveries in cancer biology and translational medicine 1 . An implicit assumption has been that cell lines are clonal and genetically stable, and therefore that results obtained in one study can be readily extended to another. However, findings involving cancer cell lines are often difficult to reproduce 2, 3 , leading investigators to conclude that the findings were either weak or the studies not carefully conducted. For example, although pharmacogenomic profiling of large collections of cancer cell lines have proven to be mostly reproducible, some discrepancies in drug sensitivity remain unexplained [4] [5] [6] [7] [8] [9] [10] [11] . We hypothesized that cancer cell lines are neither clonal nor genetically stable, and that this instability can generate variability in drug sensitivity.
Cross-laboratory comparisons
To test the hypothesis that clonal variation exists within established cell lines, we reanalysed whole-exome sequencing data from 106 cell lines generated by both the Broad Institute (the Cancer Cell Line Encyclopedia (CCLE)) and the Sanger Institute (the Genomics of Drug Sensitivity in Cancer (GDSC)), using the same analytical pipeline for both datasets (Methods).
As expected, estimates of the allelic fraction of germline variants were nearly identical across the two datasets (median r = 0.95), indicating that sequencing artefacts do not substantially contribute to the erroneous appearance of low allelic fraction calls. However, the degree of agreement in allelic fraction for somatic variants was substantially lower (median r = 0.86; P < 2 × 10 −16 ; Fig. 1a , Extended Data Fig. 1a and Supplementary Table 1 ). Moreover, a median of 19% of the detected non-silent mutations (range, 10-90%) were identified in only one of the two datasets (Extended Data Fig. 1b ). Similarly, 26% of genes that had copy number alterations (CNAs; which are also known as copy number variants) (range, 7-99%) were discordant (Extended Data Fig. 1c-e ). These results indicate that genetic variability across cultures of the same cell line is common. Indeed, a median of 22% of the genome was estimated to be affected by subclonal events across 916 CCLE cell lines (Extended Data Fig. 1f ), suggesting that changes in subclonal composition may underlie the observed differences.
Genetic variation across 27 MCF7 strains
We performed extensive genomic characterization of 27 versions (hereafter called 'strains') of the commonly used oestrogen receptor (ER)-positive breast cancer cell line MCF7 [12] [13] [14] (Methods, Extended Data Figs. 1g-n, 2a, b and Supplementary Table 2 ), including 19 strains that had not undergone drug treatment or genetic manipulation, 7 strains that carried a genetic modification generally considered to be neutral (for example, introduction of a reporter gene, Cas9 or a DNA barcode), and one strain (MCF7-M) that had been expanded in vivo in mice following anti-oestrogen therapy. Strain M was found to be an outlier, consistent with having been through strong bottlenecks, and was therefore excluded from downstream quantitative analyses.
Ten chromosome arms (25% of the genome) were differentially gained or lost in a pairwise comparison of strains (Supplementary Table 3 ). We detected 283 genes with copy number gains and 405 genes with copy number losses (compared to basal ploidy) in at least one strain. Only a small minority of these changes (13% of gains and 21% of losses) were detected in all strains. Of these changes, 7% of gains and 13% of losses were detected in only a single strain, and the remaining events were observed variably across strains ( Fig. 1b and
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Supplementary Table 4 ). The differential events included genes commonly gained or lost in breast cancer (for example, TP53, PTEN, EGFR, PIK3CA and MAP2K4; Extended Data Fig. 3a ). For example, PTEN was deleted in 17 strains and retained in the other 10 ( Fig. 1c) . Similarly, the oestrogen receptor gene ESR1 was gained in 12 strains, lost in 6 and unaltered in 9 (Fig. 1c ), and this correlated with differential expression of ERα (P = 0.009; Extended Data Fig. 3b, c and Supplementary Discussion).
Genetic variation was similarly observed at the level of point mutations, small insertions or deletions (indels) and chromosomal translocations. Only 35% of 95 non-synonymous single nucleotide variants (SNVs) and indels that affected the coding sequence or splice regions were shared by all strains: 29% were unique to a single strain, and the remaining were present in a subset of strains ( Fig. 1d , e, Extended Data Fig. 3dj , Supplementary Tables 5, 6 and Supplementary Discussion). Similar, albeit lower, variability was observed among mutations listed as recurrent in the COSMIC database 15 , consistent with COSMIC mutations tending to be clonal mutations of the founding populations (Extended Data Fig. 3f ).
Unsupervised hierarchical clustering analysis, in which genetic distance was reflected by the branch lengths of the dendrogram, generated a branch structure that accurately reflected the history of the strains. For example, strain M, which had been subjected to in vivo passaging and drug treatment, was the most genetically distinct; the 11 strains used by the connectivity map project 16 over a 10-year period clustered tightly together; and sibling strains D and E, which were only a few passages apart, were the closest to each other (Fig. 1f , g and Extended Data Fig. 3g ). The genetic distance between strains appeared to be affected more by passage number and genetic manipulation than by freeze-thaw cycles ( Fig. 1h and Extended Data Fig. 4 ).
Sources of variation
Analysis of variant allelic fractions revealed extensive subclonality across strains (Fig. 2a, b and Extended Data Fig. 5a ). For example, all 27 strains had a PIK3CA-activating mutation (G1633A), but the allelic fraction varied from 0.21 to 0.70 (Extended Data Fig. 5b ). On the basis of allelic fractions and copy number status, 45% of all observed mutations were determined to be subclonal (P < 0.01 in a correlations between the Broad and the Sanger cell lines (n = 106), for germline (black) and somatic (grey) SNVs. One-tailed paired Wilcoxon rank-sum test. b, The number of gene-level CNAs shared by each number of MCF7 strains. Red, gains; blue, losses. c, CNAs of two genes, PTEN and ESR1. d, The number of non-silent point mutations shared by each number of MCF7 strains. e, The allelic fraction of inactivating mutations in the tumour suppressor PTEN. f, Top, unsupervised hierarchical clustering of 27 MCF7 strains based on CNA profiles derived from low-pass whole-genome sequencing. Orange, strain M subjected to in vivo passaging and drug treatment; blue, 11 connectivity map strains cultured in the same laboratory without extensive passaging; green, strains D and E cultured in the same laboratory and separated by few passages; purple, strains I and K separated by Cas9 introduction. Bottom, corresponding heat map of the CNA landscapes of the strains relative to the median CNA landscape. Red, gains; blue, losses. g, Top, unsupervised hierarchical clustering of 27 MCF7 strains, based on their non-silent SNV profiles derived from deep targeted sequencing. Colours as in f. Bottom, corresponding heat map of the mutation status of non-silent mutations across strains. Mutations that were identified in a subset of the strains at AF > 0.05 are shown. Yellow, mutation present; grey, mutation absent. h, Comparison of the magnitude of CNAs observed following multiple freeze-thaw cycles (n = 9; R, A and S versus W, X and Y), extensive passaging (n = 5; D versus L versus AA, B versus I and P), and genetic manipulations (n = 4; AA versus O, B versus C, I versus J and K). Bar, median; box, 25th and 75th percentiles; whiskers, 1.5× IQR of lower and upper quartile; circles, data points. Two-tailed Wilcoxon rank-sum test. binomial test). PyClone 17, 18 , which reconstructs subclonal structure by clustering mutations with similar cellular prevalence, found multiple subclones within each MCF7 strain, with varying abundance across strains ( Fig. 2c ). Indeed, for 43% of the non-silent SNVs, cellular prevalence differed by >50% across strains (Extended Data Fig. 5c, d and Supplementary Table 7 ).
We next investigated whether clonal dynamics were stochastic or the product of selection. We barcoded MCF7 cells (strain D) and evaluated the change in barcode representation over time under five culture conditions, each in five replicates. We reasoned that if clonal dynamics were stochastic, distinct barcoded populations would emerge in independent replicates. By contrast, if pre-existing subclones were selected under different conditions, enrichment of the same barcodes would be observed in replicate cultures 19 . Unsupervised hierarchical clustering by barcode representation revealed that biological replicates clustered together ( Fig. 2d and Supplementary Table 8 ), indicating that preexisting subclones are indeed selected by changes in culture conditions. Next, we characterized the genetic stability of three wild-type singlecell-derived MCF7 clones and five single-cell-derived clones with a 'neutral' genetic manipulation (stable expression of a luciferase reporter; Methods, Extended Data Fig. 5e and Supplementary Tables 9, 10 ). Clones derived from the same parental population differed in their mutational landscapes: a median of 15% of the non-silent SNVs detected in the wild-type parental population (range, 13% to 16%), were not observed in their single-cell-derived progeny or vice versa (Extended Data Fig. 5f, g) .
Moreover, the single-cell clones continued to evolve into heterogeneous populations. We propagated two clones for 8-14 months and sequenced their DNA at multiple time points (Supplementary Tables 9, 10). A median of 13% of the non-silent SNVs (range, 8-16%) were not shared between time points (Extended Data Fig. 5g ). Similar results were observed based on cytogenetic analysis (Extended Data Fig. 5h -k and Supplementary Table 11 ), indicating that even single-cell-derived clones are genomically unstable.
Gene expression variation
We next measured transcriptomic variation across the MCF7 strains using the L1000 assay 16, 20, 21 (Supplementary Table 12 ). Despite an overall similarity in their global gene expression profiles ( Fig. 3a and Extended Data Fig. 6a ), the 27 strains also showed extensive expression variation: 654 genes (median; range, 10-1,574) were differentially expressed by at least twofold between pairs of strains (P < 0.05, Q < 0.05), and the differentially expressed genes converged on important biological pathways (Extended Data Fig. 6b-d and Supplementary Table 13 ). Notably, the 27 strains clustered similarly in the space of mutations and expression profiles, and the expected downstream consequences of genetic mutations were observed in the gene expression variation (Figs. 1f, g, 3b-g, Extended Data Fig. 6e -i and Supplementary Table 14 ). For example, strains with inactivating PTEN mutations or activating PIK3CA mutations had decreased PTEN and increased mTOR gene expression signatures, respectively (Fig. 3e , f and Extended Data Fig. 6g -i). Similarly, copy number loss of ESR1 was associated with reduced oestrogen signalling ( Fig. 3g and Extended Data Fig. 6g ).
We further explored gene expression heterogeneity using singlecell RNA sequencing of 26,465 individual cells from two parental and four single-cell-derived clones (Methods, Extended Data Fig. 6j -r and Supplementary Discussion). Unsupervised clustering showed that cells from the single-cell-derived clones did not cluster independently, but were mixed with the parental population, indicating high similarity in overall gene expression ( Fig. 3h and Extended Data Fig. 6o ). Notably, the extent of expression heterogeneity among the single-cell-derived clones was not substantially lower than the heterogeneity of the parental population (Extended Data Fig. 6p ), and increased with time in culture (Extended Data Fig. 6q -r, Supplementary Table 15 and Supplementary Discussion). These results indicate that variation in gene expression arises de novo, in addition to reflecting selection of pre-existing subclones 22 . Bottom, corresponding heat map of the allelic fractions of non-silent mutations present in a subset of the strains. b, The distribution of allelic fractions of non-silent mutations across strains. c, The cellular prevalence of mutation clusters across MCF7 strains identified by a PyClone analysis. Mutation clusters with differential abundance (a difference in cellular prevalence (ΔCP) > 0. 15 
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Verification in additional cell lines
To exclude the possibility that the variation that we observed across MCF7 strains was unique to that cell line, we repeated genomic analyses on 23 strains of the commonly used lung cancer cell line A549 23 (Extended Data Fig. 2c, d and Supplementary Tables 16-20) . We observed a similar level of molecular variation across these strains (Extended Data Fig. 7 ). For example, loss of CDKN2A, the most significantly deleted gene in lung adenocarcinomas 24 , was detected in 5 strains, but a normal copy number was retained in the other 18 (Extended Data Fig. 7f ). Whereas transcriptome analyses showed that oestrogen signall ing was the most variable pathway in MCF7 cells (Extended Data Fig. 6c and Supplementary Table 13 ), KRAS signalling was the most variable pathway in A549 (Extended Data Fig. 7n and Supplementary Table 20) , a commonly used model of KRAS-dependent cancer.
The generalizability of our findings was further confirmed by deep targeted sequencing of multiple strains from 11 additional cell lines (Extended Data Fig. 8 and Supplementary Tables 21-24) . Notably, genomic instability was not limited to transformed cancer cell lines (Supplementary Discussion). For example, the variation across 15 strains of MCF10A 25 , a non-transformed human mammary cell line, was as high as the variation that we found in MCF7 cancer cells (median discordance, 26%; range, 17-40%; Extended Data Fig. 8a , h).
Functional consequences of genomic variation
The extensive genomic variation across strains was associated with variation in biologically meaningful cellular properties. We examined several measures of basic cellular function, including doubling time and cell morphology, using quantitative live cell imaging 26 (Methods) . MCF7 strains varied in doubling times by as much as 3.5-fold (median, 31 h; range, 22-78 h; Extended Data Fig. 9a, b ). Similarly, cell size and shape were highly variable across strains (Extended Data Fig. 9c-f and Supplementary Table 25 ). Clustering based on morphological traits was similar to clustering based on genomics or transcriptomics (Extended Data Fig. 9g ), and genomic features correlated with proliferation (Extended Data Fig. 9h , i and Supplementary Discussion).
Genomic instability also had major effect on drug response. We measured cell viability following treatment with 321 drugs at a single concentration (5 μM) across the 27 MCF7 strains ( Supplementary  Table 26 ). Of these, 55 compounds had strong activity (>50% growth inhibition) against at least one strain. However, at least one strain was entirely resistant (<20% growth inhibition) to 48 out of these 55 (87%) active compounds (Fig. 4a, b and Extended Data Fig. 10a ). The same phenomenon was observed at a more stringent threshold: of 42 compounds with strong activity in at least two strains, 33 (79%) were inactive in at least two strains (Extended Data Fig. 10b -d, j and Supplementary Discussion). All 33 differentially active compounds were validated in an eight-point dose-response analysis of each of the 27 strains (median Spearman's ρ = 0.42 between screens, P = 3 × 10 −9 ; Extended Data Fig. 10k , Supplementary Table 27 and Supplementary Discussion).
The high degree of variability in drug response cannot be explained by irreproducibility of the assay. First, replicate treatments yielded highly concordant results (median Pearson's r = 0.97, P < 2 × 10 −16 ; Extended Data Fig. 10l ). Second, compounds with the same mechanism of action had similar patterns of activity across strains ( Fig. 4a , c; P = 3 × 10 −7 ). For example, the same activity pattern was observed for three proteasome inhibitors (bortezomib, MG-132 and carfilzomib; Fig. 4d ), and was associated with biochemically measured differential proteasome activity (Extended Data Fig. 10m -o). Third, for 82% of differentially active compounds, we found differential gene expression signatures of the mechanism of action 27 of the compounds between sensitive and insensitive strains (P = 2 × 10 −5 ; Fig Indeed, drug response was associated with transcriptional differences in relevant pathways. For example, strains sensitive to CDK inhibitors had an upregulated cell cycle signature and strains sensitive to PI3K inhibitors had an upregulated mTOR signature ( Fig. 4f , g and Extended Data Fig. 10p, q) . Notably, the strains that were the most resistant to treatment in general (strains M and Q) showed downregulation of drug metabolism pathways (Extended Data Fig. 10v ). Differences in proliferation rate did not explain the majority of the observed differential drug activity (median Spearman's ρ = 0.017, P = 0.60; Supplementary Table 30 ).
Genetic variation could be linked directly to differential drug response. For example, genetic inactivation of PTEN was associated with decreased PTEN and increased AKT expression signatures (Figs. 1c, e, 3e, f), and increased sensitivity to the AKT inhibitor IV ( Fig. 4h , i). Similarly, ESR1 loss was associated with reduced oestrogen signalling (Figs. 1c, 3g), which was in turn associated with reduced sensitivity to tamoxifen or oestrogen depletion ( Fig. 4j and Extended Data Fig. 10w-x ). More broadly, clustering of the MCF7 strains based on their drug response was highly similar to clustering based on genetics or gene expression (Figs. 1g, 2a, 3b, 4a, Extended Data Fig. 11a and Supplementary Discussion). Genome-wide CRISPR screens showed that genetic dependencies were affected by genomic variation similar to pharmacological dependencies (Extended Data Fig. 11b -f, Supplementary Table 31 and Supplementary Discussion), and functional analyses revealed that single-cell-derived clones remained Fig. 1 . c, Schematics of the analysis performed to evaluate the association between genetic variation and transcriptional programs. d, Arm-level gains and losses are associated with significant up-and downregulation of genes transcribed from the aberrant arms. e, Gene-level CNAs are associated with significant dysregulation of the perturbed pathways. For example, upregulation of mTOR signalling was found in strains that had lost a copy of PTEN. f, Point mutations are associated with significant dysregulation of the perturbed pathways. For example, upregulation of mTOR signalling was found in strains with an inactivating PTEN mutation. g, Copy number loss of ESR1 is associated with significant downregulation of the oestrogen response. h, A t-SNE plot of single-cell RNA-sequencing data from a parental population and three of its single-cell-derived clones. scWT3-5, single-cell wild-type clone 3-5.
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phenotypically unstable (Extended Data Fig. 11g -i and Supplementary Discussion).
We thus hypothesized that variation across otherwise isogenic strains might be harnessed to discover mechanisms of drug sensitivity and resistance. Indeed, we found that basal gene expression profiles across the 27 MCF7 strains could be more readily connected to the mechanism of action of active drugs than did larger panels of breast cancer cell lines derived from different patients 5, 8 (Fig. 4k , Supplementary Table 32 and Supplementary Discussion).
Discussion
Our results show that established cancer cell lines, generally thought to be clonal, are in fact highly genetically heterogeneous. This heterogeneity results both from clonal dynamics (that is, changes in the abundance of pre-existing subclones) and from continuous instability (that is, the appearance of new genetic variants). Moreover, genetic heterogeneity leads to varying patterns of gene expression, which in turn result in differential drug sensitivity. These findings have a number of important implications, which are summarized in Extended Data Table 1 . Colours as in Fig. 1 . Bottom, corresponding heat map of the percentage of viability change for each compound across strains. Compounds are coloured based on their mechanism of action. b, Classification of the screened compounds based on their differential activity. Consistent, viability change <−50% for all strains; variable, viability change <−50% for some strains and >−20% for other strains; intermediate, viability change in between these values. c, Comparison of the similarity in drug response patterns between compounds that share the same mechanism of action (n = 39) and compounds that work through different mechanisms (n = 1,439). One-tailed Wilcoxon rank-sum test. d, Highly similar differential drug response patterns for three proteasome inhibitors: bortezomib, MG-132 and carfilzomib. Each data point represents the mean of two replicates. The number of data points per strain is mentioned in parentheses. The response pattern with no drug (DMSO control) is presented for comparison. e, Schematics of the analysis performed to evaluate the association between drug response and transcriptional variation. f, Upregulation of the KEGG cell cycle signature in strains sensitive to the cell cycle inhibitor alsterpaullone (8 sensitive and 15 resistant strains). g, Upregulation of mTOR signalling in strains sensitive to the PI3K inhibitor BKM-120 (8 sensitive and 5 resistant strains). h, Upregulation of the genes that are upregulated when PTEN is knocked down in strains sensitive to AKT inhibitor IV (6 sensitive and 9 resistant strains). i, Strains with PTEN mutation (n = 12) respond more strongly to AKT inhibitor IV than strains without the mutation (n = 14). j, Strains with ESR1 copy number loss (n = 5) grow better in oestrogen-depleted medium than strains without ESR1 loss (n = 21). k, Comparison of gene set enrichment analysis-based MoA identification between the MCF7 cohort and the CTD 2 (n = 15) and GDSC (n = 19) cohorts across matched drugs. Two-tailed Fisher's exact test. For all box plots: bar, median; box, 25th and 75th percentiles; whiskers, 1.5× the interquartile range of the lower and upper quartile; circles, data points.
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We found that changes in clonal composition underlie much of the observed variability in cell line behaviour. Such clonal composition changes follow selection by particular conditions (for example, growth medium) or by genetic manipulations associated with a population bottleneck. The genetic distance between cell line strains was strongly correlated with their gene expression distance and with their drugresponse distance. Cell line diversification can therefore be estimated using inexpensive profiling methods (Extended Data Fig. 11j ). To facilitate routine assessment of cell line diversification, we have created the Cell STRAINER (strain instability profiler) portal (https://cellstrainer. broadinstitute.org), where users can upload cell line genomic data and measure their strain's genetic distance from a reference.
Variation within cancer cell lines can also be useful in at least two ways. First, deeper characterization (for example, by single-cell sequencing) of the heterogeneity within cultures of common cell lines could enable the study of cooperative and competitive interactions between cancer cell populations 28, 29 and mechanisms of pre-existing drug resistance 19 . Second, owing to their matched genetic background, naturally occurring 'isogenic-like' strains could help to uncover the association between molecular features and phenotypes such as drug response.
We conclude that cancer cell lines remain a powerful tool for cancer research, but their genomic evolution leads to a high degree of variation across cell line strains, which must be considered in experimental design and data interpretation. 
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The authors declare no competing interests. The genetically manipulated single-cell-derived MCF7 GREB1 and MCF7 ESR1 clones were generated using CRISPR-Cas9-mediated genome engineering to insert a NanoLuciferase reporter gene into the 3′ UTR of the respective genes. In brief, a selectable reporter gene cassette was engineered using the EMCV IRES element to drive expression of the destabilized NLucP reporter gene (Promega) fused to the N terminus of the BSR blasticidin-resistance gene (Invivogen) containing a P2A self-cleaving peptide element. For targeting GREB1, the reporter gene cassette was subcloned into a construct containing approximately 2 kb of the GREB1 gene surrounding the termination codon in exon 33, such that the reporter gene cassette is located 9 bp downstream of the GREB1 termination codon in the resulting mRNA hybrid transcript. A GREB1-specific sgRNA was generated that recognized the sequence GCTGACGGGACGACACATCTG on the sense strand, using a PAM site that is adjacent to the GREB1 termination codon. For targeting ESR1, the reporter gene cassette was subcloned into a construct containing approximately 2 kb of ESR1 gene surrounding the termination codon in exon 8, such that the reporter gene cassette is located 21 bp downstream of the ESR1 termination codon in the resulting hybrid mRNA transcript. An ESR1-specific sgRNA was generated that recognized the sequence GTCTCCAGCAGCAGGTCATAG on the anti-sense strand, using a PAM site that is 160 bp upstream of the ESR1 termination codon. Corresponding Cas9 sgRNA and targeting construct pairs were transiently transfected into MCF7 cells using Lipofectamine 2000 (Thermo Fisher Scientific). After growth for seven days, the cells were cultured in medium containing 5 μg ml −1 blasticidin to select for the desired recombinants. Single-cell clones were then isolated by limitingdilution single-cell cloning in 96-well plates. Growth rate analysis. Cells were seeded in triplicates in white, clear-bottom, 96-well plates (Corning, 3903), at a density of 5,000 cells per well. Plates were incubated in an IncuCyte ZOOM instrument (Essen Bioscience) at 37 °C, 5% CO 2 . Four non-overlapping phase-contrast images (10×) were taken every 2 h for a total of 160 h. IncuCyte ZOOM software (version 2015A) was used to calculate the mean confluence per well at each time point (filtered to exclude objects smaller than 100 μm 2 ), and averaged across wells to calculate the mean confluence per strain. Doubling times were calculated for each strain, using the formula T doubling = (log 2 (ΔT))/(log(c 2 ) − log(c 1 )), in which c 1 and c 2 were the minimum and maximum percentage confluency during the linear growth phase, respectively, and ΔT was the time elapsed between c 1 and c 2 . To account for potential differences in cell recovery following seeding, t = 0 h was defined as the first time point in which the mean strain confluency surpassed a threshold of 15%. To examine the effect of oestrogen depletion on the growth of MCF7 strains, cells were cultured either in standard conditions (described above) or in oestrogen-depleted conditions: RPMI 1640 without phenol red (Life Technologies), with 10% charcoal-stripped fetal bovine serum (Life Sciences) and 1% penicillin-streptomycin-glutamine (Life Technologies). Comparison between standard and oestrogen-depleted conditions was performed by calculating the fold change in doubling time between the two conditions. Cell painting. Cells were plated in triplicate at a density of 1,000 cells per well, and then stained and fixed as previously described 26, 30 . Images were taken on a Perkin-Elmer Opera Phenix microscope with a 20×/1.0NA water-immersion lens. Image quality control was carried out as previously described 31 32 was applied to identify CNAs of large genomic segments, chromosome arms and whole chromosomes. First, the genome was divided into 1-Mb bins and read counts were generated for each bin using the HMMcopy Suite (http://compbio.bccrc.ca/software/hmmcopy/). The raw read counts were then normalized to correct for GC content and mapability biases using the HMMcopy R package 33 , generating corrected read counts for each 1-Mb bin. Segmentation and copy number prediction for each sample were performed using ichorCNA v.0.1.0 (https://github.com/broadinstitute/ichorCNA), which is optimized for low-coverage whole-genome sequencing. Parameters were initialized based on prior knowledge: -normal = 0.01, -ploidy = c(3, 3.5, 4), -txnE = 0.99999, -txnStrength = 10,000, -maxCN = 8. Remaining parameters were set to the default. For bin-level comparison between strains, we used the log 2 -transformed corrected read counts and determined gain and loss status using thresholds of 0.1 and −0. Article reSeArcH tool in GATK (http://www.broadinstitute.org/cancer/cga/indelocator). Consecutive variants in the same codon were reannotated to maximize the effect on the codon and marked as 'Phased' variants. MuTect was run in paired mode, pairing the MCF7 or A549 samples to a normal sample, CEPH1408. Mutations were called if detected in >2% of the reads (AF > 0.02). All SNVs, indels and phased variants were annotated with Variant Effect Predictor 39 . Variants were filtered against the 6,500 exome release of the Exome Sequencing Project database. Variants that were represented more than once in either the African-or European-American populations and were found less than twice in COSMIC were considered to be germline (given that no matched normal samples were available). A germline filter was not applied to the downstream analyses, as changes in such mutations between strains of the same cell line would have to arise in culture and may be functionally relevant. Non-silent mutations were considered to be those with the following BestEffect Variant Classification: missense, initiator codon, nonsense, splice acceptor, splice donor, splice region, frameshift, inframe insertion or inframe deletion. Mutations that appeared more than once in COSMIC were regarded as COSMIC mutations. The complete lists of variants (SNVs, indels and phased) for MCF7, A549 and additional cell lines are provided in Supplementary Tables 5, 17 and 23, respectively.
Additional information
CNAs were identified using RobustCNV, an algorithm that relies on localized changes in the mapping depth of sequenced reads in order to identify changes in copy number at the sampled loci (M. Ducar et al. manuscript in preparation). Systematic bias in mapping depth was reduced using robust regression, fitting the observed tumour mapping depth against a panel of normal samples captured using the same bait set. Observed values were then normalized against predicted values and expressed as log 2 ratios. A second normalization step was performed to remove GC bias, using a LOESS fit. log 2 ratios were centred on segments that were determined to be diploid based on the allele fraction of heterozygous SNPs in the targeted panel. Normalized coverage data were next segmented using Circular Binary Segmentation 40 with the 'DNAcopy' Bioconductor package. Finally, segments were assigned gain, loss or normal-copy calls using a cutoff derived from the within-segment standard deviation of post-normalized mapping depths. Owing to the high data quality and low within-segment standard deviation, a cutoff of around 0.1 was applied to all samples. Segment calls were summarized to gene calls by assigning them to capture intervals, and then counting the interval calls for each gene. Gene level calls were determined according to the following rules: 'gain' = '+' calls >50%; 'loss' = '−' calls >2 or in 100%; 'gain + loss' = '−' calls >2 times and '+' calls <50%; 'mixed' = '+' and '-' calls in the same gene, but below threshold; 'normal+' = '+' calls, but below threshold; "'normal−' = '−' calls, but below threshold; 'Normal' = no '+' or '−' calls. The complete list of CNAs for MCF7, A549 and additional cell lines are provided as Supplementary Tables 4, 16 and 22, respectively.
For a subset of 60 genes (listed in Supplementary Table 2 ), rearrangements (structural variants) were detected using BreaKmer 41 , which is designed to detect larger genomic structural variations from single-sample-aligned short-read target-captured high-throughput sequencing data. In brief, the method extracts 'misaligned' sequences from a targeted region, such as split reads and unmapped mates, assembles a contig from these reads, and re-aligns the contig to make a variant call. It classifies detected variants as 'insertions/deletions' , 'tandem duplications' , 'inversions' and 'translocations' . The complete lists of structural variants for MCF7 and A549 are provided in Supplementary Tables 6 and 18 , respectively. Rearrangements were visualized using the 'Circos' visualization tool 40 . Clonality analysis. To resolve clonal dynamics and composition, we applied the PyClone algorithm v.0.13.0 (https://bitbucket.org/aroth85/pyclone/wiki/Home) to the measured allelic fractions, accounting for copy number, loss of heterozygosity and cellularity 17 . PyClone enabled us to follow clonal dynamics throughout the evolution of cell populations 17, 18 . For copy number input, we used results from ichorCNA segmentation and copy number predictions. Mutations with <50 read depth were excluded. The following parameters were used for PyClone: 10,000 iterations, 1,000 burn-in, 'total_copy_number' for the prior. We also performed multi-sample analysis using PyClone, to determine the changes in clonal composition across strains. For the multi-sample analysis, mutations were selected as the union set across all 27 strains. The same parameters were used for PyClone multi-sample analysis as for the individual-sample runs. DNA barcoding experiment. Degenerate oligonucleotides for sgRNA-barcode library construction were synthesized by IDT and cloned into lentiGuide-Puro 42 by Gibson assembly, as previously described 43 . Approximately 300 μg of Gibson product was transformed into 25 μl of Endura electrocompetent cells (Lucigen). After a 1-h recovery period, 0.1% of transformed bacteria were plated in a tenfold dilution series on ampicillin-containing plates to determine the number of successful transformants. The remainder of the transformed bacteria were cultured in 50 ml of LB with 50 μg ml −1 ampicillin for 16 h at 30 °C. Plasmid libraries were extracted using a Plasmid MidiPlus kit (Qiagen) and sequenced to a depth of 6.2 million reads on a Illumina Miniseq, corresponding to 6× coverage of >1 million barcodes.
Lentivirus was prepared by transfecting a total of 10 million HEK293FT cells, as previously described 43 . The MCF7-D strain was cultured in standard conditions (described above), and four million cells were infected with a low multiplicity of infection (20-30%) to reduce the probability of each cell being infected with more than one barcode. Cells underwent puromycin selection, and the final cell pool contained approximately 160,000 unique barcodes. Cells were expanded for the experiment, and five million cells were then plated into 25 tissue culture flasks. Five culture conditions were then applied (with five replicates per condition): (1) RPMI 1640 (Life Technologies) with 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin-streptomycin-glutamine (Life Technologies); (2) DMEM (Life Technologies) with 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillinstreptomycin-glutamine (Life Technologies); (3) RPMI 1640 without phenol red (Life Technologies), with 10% charcoal-stripped fetal bovine serum (Life Sciences) and 1% penicillin-streptomycin-glutamine (Life Technologies); (4) RPMI 1640 (Life Technologies) with 10% fetal bovine serum (Sigma-Aldrich), 1% penicillinstreptomycin-glutamine (Life Technologies) and 0.05% DMSO (Sigma-Aldrich); (5) RPMI 1640 (Life Technologies) with 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin-streptomycin-glutamine (Life Technologies), supplemented for the first 48 h with 500 nM bortezomib (Selleckchem, S1013). After five weeks of culture, DNA was extracted and barcode abundance was assessed by DNA sequencing, as previously described 43 . Libraries were sequenced to a median depth of 4.2 million reads, corresponding to a barcode coverage of >26×. Transcriptional profiling with L1000. The L1000 expression-profiling assay was performed as previously described 16 . First, mRNA was captured from cell lysate using an oligo dT-coated 384-well Turbocapture plate. The lysate was then removed, and a reverse-transcription mix containing MMLV was added. The plate was washed and a mixture containing both upstream and downstream probes for each gene was added. Each probe contained a gene-specific sequence, along with a universal primer site. The upstream probe also contained a microbead-specific barcode sequence. The probes were annealed to the cDNA over a 6-h period, and then ligated together to form a PCR template. After ligation, Hot Start Taq and universal primers were added to the plate. The upstream primer was biotinylated to allow later staining with streptavidin-phycoerythrin. The PCR amplicon was then hybridized to Luminex microbeads via the complimentary, probe-specific barcode on each bead. After overnight hybridization the beads were washed and stained with streptavidin-phycoerythrin to prepare them for detection in Luminex FlexMap 3D scanners. The scanners measured each bead independently and reported the bead colour and identity and the fluorescence intensity of the stain. A deconvolution algorithm converted these raw fluorescence intensity measurements into median fluorescence intensities for each of the 978 measured genes, producing the GEX level data. These GEX data were then normalized based on an invariant gene set, and then quantile-normalized to produce QNORM level data. An inference model was applied to the QNORM data to infer gene expression changes for a total of 10,174 features. Per-strain gene expression signatures were calculated using a weighted average of the replicates, for which the weights are proportional to the Spearman correlation between the replicates. Transcriptional profiling data analysis. To examine how newly profiled MCF7 and A549 cells compared in gene expression to a previously acquired collection of cell line profiles (untreated samples that served as controls for connectivity map perturbational experiments), we used t-SNE. Profiles were restricted to untreated profiles from the nine core connectivity map cell lines, and to batches with multiple untreated profiles. Because samples were first clustered based on their project codes, batch effect was next removed using the COMBAT algorithm 44 . t-SNE analysis was applied to the batch-corrected data and visualized using a scatter plot. Analysis was completed using the 'Rtsne' R package version 0.13 62 . For the comparison of transcriptional variation across the nine core connectivity map cell lines, the collection of untreated profiles generated with the L1000 assay was used. Five profiles from each cell line were randomly chosen, and the expression variance of the 978 L1000 landmark genes was calculated for each cell line. For the comparison of L1000 gene expression data to the Cancer Cell Line Encyclopedia (CCLE) gene expression profiles, RNA-sequencing (RNA-seq) and Affymetrix gene expression profiles were downloaded from the CCLE website (https://portals. broadinstitute.org/ccle/data). Data within each platform were processed using invariant set scaling, which adjusts profiles according the expression of 80 'invariant' genes, followed by quantile normalization 16 . The ranked gene expression order of the 978 landmark genes was compared using a Spearman's correlation. Chemical screening. MCF7 strains were tested against a small-molecule informer set library of 321 anti-cancer compounds, assembled by the Cancer Target Discovery and Development (CTD 2 ; https://ocg.cancer.gov/programs/ ctd2/data-portal), using the same principles as those described in the Cancer Therapeutics Response Portal 8, 45 . The list of screened compounds is included as Supplementary Table 26 . Cells were seeded in their culture medium in white, 384well plates (Corning, 3570) at an initial density of 2,500 cells per well and incubated overnight at 37 °C, 5% CO 2 . The next day, 25 nl (for primary screen) or 100 nl Article reSeArcH (for confirmation dose-response screen) of compound stocks in DMSO were added by pin transfer. Plates were incubated for 72 h, cooled at room temperature for 10 min, and viability was measured using the CellTiter-Glo luminescent cell viability assay (Promega), according to the manufacturer's protocol. After 10 min of incubation, luminescence was read on a Perkin Elmer Envision reader, at a speed of 0.1 s per well. Chemical screening data analysis. Data were analysed in Genedata Screener version 13.0, using the normalization method 'neutral controls' , for which the median of the 32 DMSO wells on each plate was set to 0% activity and 0 raw signal was set to -100%. Positive controls (20 μM MG-132 or 20 μM bortezomib) were included on all plates (16 wells each) but were not used for normalization owing to variability in the response across cell lines. Dose-response curves were fit using the 'Smart Fit' strategy in Genedata. The percentage of effect was defined as the high-concentration asymptote (sinf) and the qEC 50 was the concentration at which the fitted curve crossed the inhibitory value representing half of the maximal effect (%). In addition, parameters were calculated at which the curve crossed absolute inhibitory values of 30% or 50% regardless of maximal effect (AbsEC 30 and AbsEC 50 , respectively). AUC calculations were performed as previously described 8 : curves were fit with nonlinear sigmoid functions, forcing the low concentration asymptote to 1 using a three-parameter sigmoidal curve fit. The AUC for each compound-strain pair was calculated by numerically integrating under the eightpoint concentration-response curve. For visualization purposes, drug response curves were fit with a four-parameter log-logistic function, based on normalized viability data from which the lowest dose viability had been subtracted. Plots were generated using the "LL.4" function in the 'drc' R package (https://cran.r-project. org/web/packages/drc/). To examine a potential link between proliferation rate and differential drug response, doubling times were compared against the AUC values of the 33 differentially-active compounds. Gene set enrichment analysis. Gene set enrichment analysis (GSEA) was performed using the 10,147 genes best inferred from the connectivity map linear model 33 , also known as the BING gene set. Samples were divided into two classes depending on the comparisons being made: samples with a genetic alteration versus samples without it; samples sensitive to a drug (>50% inhibition) versus samples insensitive to the same drug (<20% inhibition). Differential expression was calculated using the signal-to-noise metric 46 . A ranked gene list and signalto-noise values served as the input for the GSEA preranked module of GSEA, using the Java app version 3.0. The analysis was run using the 'hallmark' , 'KEGG' , 'positional' and 'oncogenic' signature collections from the Molecular Signature Database (MsigDB) 27 (http://software.broadinstitute.org/gsea/msigdb). To compare between our MCF7 panel, CTD 2 and GDSC, drug responses were downloaded from the CTRP website (https://ocg.cancer.gov/programs/ctd2/data-portal; 'v20. data.curves_post_qc' file, updated 14 October 2015) and from the GDSC website (http://www.cancerrxgene.org/downloads; 'log(IC 50 ) and AUC values' file, updated 4 July 2016). Expression profiles were downloaded from the CCLE website to match the CTD 2 drug-response data (https://portals.broadinstitute.org/ ccle/data; 'CCLE_Expression_Entrez_2012-09-29.gct' , updated 17 October 2012), and from the GDSC website to match with the GDSC drug response data (http:// www.cancerrxgene.org/downloads; 'RMA normalized expression data for cell lines' , updated 2 March 2017). Expression profiles were filtered to include only the genes that belong to the L1000 BING set. GSEA compared the expression patterns of the five strains or cell lines with the highest AUC values for each matched drug with the five strains/cell lines with the lowest AUC values for that drug. As the robustness of gene expression signatures varies, this quantitative analysis was restricted to the 50 well-defined hallmark GSEA gene sets 27 . Single-cell RNA-seq. MCF7 cells were cultured as described above. To follow transcriptional changes after drug treatment, MCF7-AA cells were exposed to 500 nM of bortezomib (Selleckchem, S1013) and collected before treatment, after 12 h of exposure (t 12 ), after 48 h of exposure (t 48 ) or after 72 h of exposure followed by drug wash and 24 h of recovery (t 96 ). Cells were washed, trypsinized, passed through a 40-μm cell strainer, centrifuged at 400g and resuspended at a concentration of 1,000 cells per μl in PBS containing 0.5% BSA. Single cells were processed through the Chromium Single Cell 3′ Solution platform using the Chromium Single Cell 3′ Gel Bead, Chip and Library Kits (10X Genomics) per the manufacturer's protocol. In brief, 7,000 cells were added to each channel and were then partitioned into Gel Beads in emulsion in the Chromium instrument, where cell lysis and barcoded reverse transcription of RNA occurred, followed by amplification, shearing and 5′ adaptor and sample index attachment. Libraries were sequenced on an Illumina NextSeq 500. Single-cell RNA-seq data analysis. Reads were mapped to the GRCh38 human transcriptome using cell ranger version 2.1.0, and transcript-per-million values were calculated for each gene in each filtered cell barcoded sample. Transcript-permillion values were then divided by 10, since the complexity of single-cell libraries is estimated to be in the order of 100,000 transcripts. For each cell, we quantified the number of expressed genes and the proportion of the transcript counts derived from mitochondrial genes. Cells with either <1,000 detected genes or >0.15 mitochondrial fraction were excluded from further analysis. Finally, the resulting expression matrix was filtered to remove genes detected in <3 cells. We focused on highly variable genes for downstream principal component analysis (PCA). For each dataset, we used the Seurat 47 (http://satijalab.org/seurat/) R package to detect variable genes based on fitting a relationship between the mean and the dispersion of each gene. We next scaled the data and regressed out unique molecular identification number and mitochondrial gene fraction to remove technical noise. The resulting scaled data were used as an input for PCA. Top significant principal components, estimated by a manual inspection of the PCA standard deviations elbow plots, were used to generate t-SNE plots. For each dataset, we used Seurat 47 (http://satijalab.org/seurat/) to identify genes that vary between samples. To detect differentially active pathways, gene ontology (GO) enrichment analysis was performed with MSigDB 27 (http://software.broadinstitute.org/gsea/msigdb) using the differentially expressed genes that passed the following thresholds: |log 2 (fold change)| > 0.25, Bonferroni-corrected P < 0.01, the gene was detected in >10% of the cells in each of the compared groups. Expression signatures for selected pathways were downloaded from MSigDB 27 . We evaluated the degree to which individual cells express a certain expression signature by using a procedure that takes into account the variability in signal-to-noise ratio, as previously reported 48 . To calculate pairwise cell distances, variable genes were detected, and the cell embedding matrix for the top significant principal components was used to calculate the Euclidean distance between every two cells within each sample. Analysis of genome-wide CRISPR screens. CERES dependency scores 49 were obtained from the Broad Institute Achilles website (https://portals.broadinstitute. org/achilles/datasets/18/download). Owing to an unusually large difference in screen quality between MCF7 and KPL1, the subtle differences in dependency status between these lines were dominated by effects related to screen quality. To remove these uninteresting sources of variation, we corrected CERES gene scores by removing their first six principal components. These components were wellexplained by experimental batch effects related to screen performance and plasmid DNA pool. Corrected dependency scores <−0.5 were defined as dependencies. Genes listed as 'pan_dependent' in the original dependency dataset were excluded from further analysis. For a more stringent overlap comparison, genes with CERES scores between −0.4 and −0.6 in MCF7 or KPL1 were further excluded. To implement the force-directed layout, described in Extended Data Fig. 11b , the full corrected dependency matrix was reduced to its top 100 principle components and a k-means clustering algorithm was run repeatedly on cell lines. Here, k is the number of clusters, and the mean cluster size (number of cell lines) divided by k is a parameter similar to perplexity in t-SNE, set to 6 for our data. Edges between cells were weighted according to the frequency with which they clustered together, with edges appearing less than 30% of the time ignored. Cells were then laid out using the SFPD spring-block algorithm 50 . Cell line RNA-seq gene expression data and reverse-phase protein array protein expression data were obtained from the CCLE website (https://portals.broadinstitute.org/ccle/data). Single-sample GSEA was calculated using the ssGSEA algorithm 51 . Chymotrypsin-like activity. MCF7 cells were plated in triplicates in 96-well plates at a density of 20,000 cells per well. After 24 h, chymotrypsin-like activity of the proteasome was assayed, using the Proteasome-Glo assay (Promega), according to manufacturer's protocol. The activity levels were normalized to the relative cell number that was measured using the fluorescent detection of resazurin dye reduction (544-nm excitation and 590-nm emission). Western blots. For PSMC2 and PSMD2 immunoblotting, cells were lysed in HENG buffer (50 mM HEPES-KOH pH 7.9, 150 mM NaCl, 2 mM EDTA pH 8.0, 20 mM sodium molybdate, 0.5% Triton X-100, 5% glycerol), with protease inhibitor cocktail (Roche Diagnostics, 11836153001). Protein concentrations were determined by BCA assay (Thermo Fisher Scientific, 23227) and proteins were resolved using SDS-PAGE for immunoblot analysis. Antibodies against the following human proteins were used: α-tubulin (ab80779, Abcam), PSMC2 (MSS1-104, Enzo Life Sciences) and PSMD1 (C-7, Santa-Cruz). Visualization was performed using the ChemiDoc MP System (Bio-Rad) and ImageLab Software (Bio-Rad) was used to quantify relative band intensities. For ERα immunonblotting, cells were lysed with a mix of 4× protein loading buffer (Li-Cor, 928-40004) and 10× NuPAGE sample reducing agent (Life Technologies, NP0009). Protein concentration was normalized by cell counting and proteins were resolved by SDS-PAGE. Antibodies against the following human proteins were used: β-actin (N-21, Santa Cruz), ERα (F-10, Santa Cruz). Visualization was performed using the Odyssey CLx imaging machine (Li-Cor) and Image Studio Software (Li-Cor) was used to quantify the relative intensities. Generation and comparison of dendrograms. Dendrograms were constructed using Euclidean distances for continuous measures and Manhattan distances for discrete measures. Complete linkage hierarchical clustering was performed in all cases. The mutation status dendrogram was based on mutations with AF > 0.05. The gene expression dendrogram was based on the 978 landmark genes directly Article reSeArcH measured by the L1000 assay. The copy number dendrograms were based on discrete calls (loss, normal or gain) assigned to each event based on its log 2 copy number ratio, using a cutoff value of ±0.1. The drug-response dendrogram was based on normalized viability values. The cell morphology dendrogram was based on the full list of the 1,784 measured cellular features. The barcode representation dendrogram was based on the log 2 transformed number of reads, including only barcodes with >1,000 reads in at least one sample. To understand how dendrograms from different sources compared, the Fowlkes-Mallows index was used, as it could capture similarities in global clustering while ignoring within-group variance 52 . The 'Bk' function in the 'dendextend' R package was used for computations and visualizations. We compared dendrograms from different sources with k values ranging from 5 to 26. A background distribution was calculated by randomly shuffling the labels of the trees 1,000 times, and calculating Bk values. The 95% upper quantile of the randomized distribution for each k was plotted. The maximum Bk value was used to estimate the degree of similarity between the compared pair of dendrograms.
Calculation of the distances between strains based on their genomic features.
CNA distance based on ultra-low-pass whole-genome DNA sequencing was determined by the fraction of the genome affected by discordant CNA calls. CNA and SNV distances based on targeted sequencing were determined by Jaccard indices, defined as the number of shared events between strains (intersection) divided by the total number of events in these strains (union). For SNVs, both the mutated gene and the exact amino acid change had to be identical to be counted as a shared event. Gene expression distances were defined as the Euclidean distances between L1000 expression profiles. Drug-response distances were defined as the Euclidean distances between drug-response profiles, after limiting the drug set to active drugs only (that is, drugs that reduced the viability of at least one strain by >50%) and setting the threshold for viability values to ±100. Comparisons across CCLE cell lines. Gene-level mRNA expression, copy number and mutation status data were downloaded from the CCLE website (https:// portals.broadinstitute.org/ccle/data; 'CCLE_Expression_Entrez_2012-09-29.gct' , updated 17 October 2012; 'CCLE_copynumber_byGene_2013-12-03.txt' , updated 27 May 2014; 'CCLE_MUT_CNA_AMP_DEL_binary_Revealer.gct' , updated 29 February 2016). The total number of point mutations and copy number changes were counted for each cell line. Chromosome arm-level events in CCLE samples were generated as previously described 53 , and the number of arm-level events was counted for each cell line. The fraction of the genome affected by subclonal events was estimated using ABSOLUTE 54 . Combined CNA-SNV genomic instability scores were calculated as described previousy 55 . The DNA repair gene set was derived from MSigDB (http://software.broadinstitute.org/gsea/msigdb), using the 'DNA_Repair' GO signature 56 . The CIN70 gene set was derived from a previous publication 57 . For each gene set, genes that were not expressed at all in the CCLE dataset were removed, and the remaining gene expression values were log 2transformed and scaled by subtracting the gene expression means. The signature score was defined as the sum of these scaled gene expression values. Comparison of Broad (CCLE) and Sanger (GDSC) genomic features. Wholeexome sequencing data for 107 matched cell lines were downloaded from the Sanger Institute (http://cancer.sanger.ac.uk/cell_lines, EGA accession number: EGAD00001001039) for the GDSC cell lines, and from the GDC portal (https:// portal.gdc.cancer.gov/legacy-archive) for the CCLE cell lines. For copy number analysis, the GATK4 somatic copy number variant pipeline was applied (https:// gatkforums.broadinstitute.org/gatk/discussion/9143/how-to-call-somatic-copynumber-variants-using-gatk4-cnv) 36, 37 . Gene-level copy number calls were generated by mapping genes from segment calls using the Consensus Coding Sequence database 58 . The gene-level values were log 2 transformed, and converted to discrete values using predefined thresholds (±0.1, ±0.3 and ±0.5). To determine the percentage of discordance for each cell line, the number of discordant CNA calls between each pair of strains was divided by the total number of genes (excluding genes with a neutral copy number call in both datasets). For analysis of somatic variants, the CCLE-Sanger merged mutation calls were downloaded from the CCLE portal (https://portals.broadinstitute.org/ccle/data), and target interval list files were generated for each of the 107 matched cell lines in CCLE. Mutation calling was performed using MuTect 38 , with default parameters and '-force_output' enabled, to count the number of reads supporting the reference and alternate allele for each variant in each cell line. For analysis of germline variants, a common target interval list file that consisted of a panel of 105,995 SNPs was generated, based on common SNVs found in 1,019 CCLE RNA-seq samples, and Mutect was applied with the same parameters as described above. Comparison of allelic fractions was performed using the subset of variants with minimum depth of coverage of 10 in both Sanger and CCLE datasets and with minimum of allelic fraction of 0.1 in at least one dataset. Out of the 107 cell lines, one cell line (Dov13) lacked any germline concordance and was thus excluded from all analyses. Cytogenetic analysis. Karyotyping was performed by KaryoLogic (www.karyologic.com/) on 50 G-banded metaphase spreads per sample. Every spread displayed multiple chromosomal rearrangements with many marker chromosomes. A marker was defined as 'a structurally abnormal chromosome that cannot be unambiguously identified by conventional banding cytogenetics' . The analysis was performed according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016 guidelines. Rare metaphases with >100 chromosomes were excluded from further analysis. e-karyotyping analysis. RNA-seq data from non-manipulated and non-treated samples of the near-diploid human cell line RPE1 were downloaded from the NCBI SRA website (https://www.ncbi.nlm.nih.gov/sra). STAR-paired aligner was used to align paired-end samples, and STAR-non-paired aligner was used to align the non-paired samples 59 . The STAR to RSEM tool 60 was used to generate the genelevel expression values using the GTEx pipeline (https://github.com/broadinstitute/ gtex-pipeline). To infer arm-level copy number changes from gene expression profiles, the RSEM values were analysed using the e-karyotyping method 61 . In brief, RSEM values were log 2 -converted, genes that were not expressed (log 2 RSEM < 1) in >20% of the samples were excluded, and expression levels of the remaining genes were floored to RSEM = 1. The median expression value of each gene across all samples was subtracted from the expression value of that gene, in order to obtain comparative values. The 10% most variable genes were removed from the dataset to reduce transcriptional noise. The relative gene expression data were then subjected to a CGH-PCF analysis, with a stringent set of parameters: Least allowed deviation = 0.5; Least allowed aberration size = 30; Winsorize at quantile = 0.001; Penalty = 18; Threshold = 0.01. CNAs exceeding 80% of the length of a chromosome arm were called arm-level CNAs.
Comparison of arm-level CNAs between cell line propagation and tumour progression.
Recurrence of chromosome arm-level CNAs during breast cancer progression was determined by their frequency in TCGA samples, as previously described 53 . Recurrence of chromosome arm-level CNAs during cell line propagation was determined by comparing the arm-level calls of the strains directly separated by extensive passaging (strain D versus strain L versus strain AA, strain B versus strains I and P), as shown in Extended Data Fig. 2a . Only arms that are recurrently gained or lost (but not both) in TCGA (Q < 0.05), and that have variable copy number status across the MCF7 panel, were considered for the comparison. Statistical analysis. The significance of the difference between genomic instability associated with different sources of genetic variation and difference between chromosome numbers at two time points of single-cell-derived clones was determined using the two-tailed Wilcoxon rank-sum test. The significance of the difference in the Euclidean distance between compounds that work through the same MoA and compounds that work through different MoA's, in the discordance of non-silent SNVs at different stages of transformation, in chromosomal instability (CIN70) and weighted-genomic integrity index (wGII) scores between cell lines derived from primary tumours and those derived from metastases, between the somatic and germline SNV Pearson correlations of the Broad-Sanger cell lines, in the Broad-Sanger somatic SNV concordance between microsatellite-stable and microsatellite-unstable cell lines and between primary tumour-derived and metastasisderived cell lines was determined using a one-tailed Wilcoxon rank-sum test. The significance of the difference in mutation cellular prevalence across strains was determined by Kruskal-Wallis test. The significance of the difference in AKT inhibitor IV sensitivity between PTEN WT and PTEN MUT strains, in the relative growth effect of ER depletion between ESR1 loss and no-ESR1 loss strains, in proteasome activity between bortezomib-sensitive and bortezomib-insensitive strains, in ERα protein expression levels between strains and in the number of arm-level CNAs between matched early-late MCF7 strains was determined using a one-tailed Student's t-test. The significance of the difference in doubling times and in sensitivity to oestrogen depletion was determined using a two-tailed Student's t-test. The significance of the correlation between the two replicates of the primary screen was determined using Pearson's correlation. The significance of the correlation between doubling time and the number of protein coding mutations, the correlation between doubling time and the fraction of subclonal mutations, the correlation between doubling time and drug response, were determined using a Spearman's correlation, excluding the broadly resistant strains Q and M. The significance of the correlation between ESR1 CERES dependency scores and oestrogen signalling and between GATA3 CERES dependency scores and GATA3 protein expression levels was determined using a Spearman's correlation. The deviation of the doubling-time-drug-response correlations from a hypothetical mean value of 0 was determined using a two-tailed one-sample t-test. The significance of the difference between the emergence and disappearance of recurrent arm-level CNAs during cell line propagation was determined using McNemar's test. The significance of the correlation between the primary and secondary drug screens was determined using a Spearman's correlation (including only compounds that were active in both screens). The significance of the directionality of drug-pathway association, and the likelihood that a mutation would be clonal given the number of reads that detected it, were determined using a binomial test. The significance between 57 . k, All CCLE cell lines ranked by their DNA-repair signature scores 56 . l, All CCLE cell lines ranked by their genomic instability scores 55 . m, All CCLE cell lines ranked by their subclonal genome fraction 54 . The vertical black line shows the rank of MCF7 in each comparison. n, Comparison of gene expression variation across multiple strains of nine cell lines, including MCF7. Box plots are the standard deviations of the expression levels for the 978 landmark genes directly measured in L1000. Bar, median; box, 25th and 75th percentiles; whiskers, data within 1.5× IQR of lower or upper quartile; circles, all data points. Fig. 3 | Genetic variation across 27 MCF7 strains. a, Variation in the copy number status of nine selected genes across 27 MCF7 strains. Red, copy number gains; blue, copy number losses. Thresholds for relative gains and losses were set at 0.1 and −0.1, respectively. b, Western blots of the relative protein expression levels of ERα across strains. The expression of β-actin was used for normalization. For gel source data, see Supplementary Fig. 1 . The experiment was repeated twice with similar results. c, Quantification of the relative expression of ERα. Strains Q and M were excluded from the comparison. Bar, median; box, 25th and 75th percentiles; whiskers, data within 1.5× IQR of lower or upper quartile; circles, all data points. One-tailed t-test. d, The allelic fractions of non-silent mutations in seven selected genes across 27 MCF7 strains. e, The number of non-silent point mutations (SNVs) across the 27 MCF7 strains. f, The number of COSMIC non-silent point mutations shared by each number of MCF7 strains. g, Top, unsupervised hierarchical clustering of 27 MCF7 strains, based on all of their SNVs. Groups of strains expected to cluster together based on their evolutionary history are highlighted, as in Fig. 1 . Bottom, a corresponding heat map, showing the mutation status of all mutations across the 27 MCF7 strains. Mutations that were identified in only a subset of the strains that were detected in above 5% of the reads (AF > 0.05) are shown. Yellow, presence of a mutation; grey, absence of a mutation. h, The number of large (>15-bp) indels and rearrangements across the 27 MCF7 strains. Grey, indels; black, rearrangements. i, The recurrence of structural variants in each of the 42 (out of 60) genes for which at least one event was detected. j, The number of structural variants shared by each number of MCF7 strains. Note that this analysis is limited to the 60 genes listed in Supplementary Table 2 . Groups of strains expected to cluster together based on their evolutionary history are highlighted, as in Fig. 1 . Bottom, a corresponding heat map, showing the allelic fractions of all mutations across the 27 MCF7 strains. Mutations that were identified in only a subset of the strains are shown. The presence of a mutation is shown in colour according to its allelic fraction. b, The allelic fractions of an activating PIK3CA mutation (top) and an inactivating TP53 mutation (bottom) across strains. c, Top, unsupervised hierarchical clustering of 27 MCF7 strains based on their SNV cellular prevalence. Groups of strains expected to cluster together based on their evolutionary history are highlighted, as in Fig. 1 . Bottom, a corresponding heat map, showing the cellular prevalence of all mutations across the 27 MCF7 strains. Mutations that were identified in only a subset of the strains are shown. The presence of a mutation is shown in colour according to its cellular prevalence. d, The distribution of the maximal differences in cellular prevalence (CP) of non-silent mutations, across 27 MCF7 strains. The peak at maximum ΔCP = 1 represents SNVs that are clonal in at least one strain but are nearly or completely absent in at least one other strain; the peak at maximum ΔCP = 0 represents SNVs that are detected at similar prevalence across all 27 strains; and the peak at maximum ΔCP ≈ 0.1 represents a group of SNVs present at CP ≈ 0.1 only in strain M. e, Description of the MCF7 single-cell-derived clones included in this study, including their parental cell line, genetic manipulations and relationship to one another. f, A heat map showing the allelic fractions of non-silent mutations in three wild-type single cell-derived MCF7 (scWT3-scWT5) clones and the parental population. The presence of a mutation is shown in colour according to its allelic fraction. g, A heat map showing the allelic fractions of non-silent mutations in five genetically manipulated single-cell-derived MCF7 clones. For two of the clones, samples were passaged for a prolonged time and sequenced at multiple time points. The presence of a mutation is shown in colour according to its allelic fraction. h, Comparison of the karyotypic variation between parental and single-cell-derived cell populations. Histograms show the distribution of chromosome numbers from the parental (light grey) and single-cell-derived (dark grey) populations. P values indicate the significance of the differences between the variations (rather than the means) of the populations using a one-tailed Levene's test (n = 50 metaphases per group). 
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Extended Data Fig. 9 | See next page for caption. MCF7 strains, based on 1,784 morphological features. h, The correlation between proliferation rate (shown as doubling time) and the number of non-silent protein-coding mutations, across 18 naturally occurring MCF7 strains (that is, strains that have not undergone drug selection or genetic manipulation). Spearman's ρ and P values indicate the strength and significance of the correlation, respectively. i, The correlation between proliferation rate (shown as doubling time) and the fraction of subclonal mutations, across 18 naturally occurring MCF7 strains. Spearman's ρ and P values indicate the strength and significance of the correlation, respectively.
Extended Data Fig. 10 | Characterization of drug-response variation across 27 MCF7 strains. a, Unsupervised hierarchical clustering of 27 MCF7 strains, based on their response to all 321 compounds in the primary screen. Groups of strains expected to cluster together based on their evolutionary history are highlighted, as in Fig. 1. b , Pie chart of the classification of the screened compounds based on their differential activity. The response to each active compound was defined as 'consistent' if viability change was <−50% for all strains, 'variable' if viability change was <−50% for some strains and >−20% for other strains, or 'intermediate' if viability change was in between these values. Classification was performed using a two-strain threshold. c, Pie charts as in b excluding strains Q and M that were generally more drug resistant. Classification was performed using a one-strain or a two-strain threshold (left and right charts, respectively). d, Pie charts as in b using an activity threshold of viability change <−80%. Classification was performed using a one-strain threshold, either including all strains (left) or excluding strains Q and M (right). e, The number of gene-level CNAs shared by each number of MCF7 strains. Red, copy number gains; blue copy number losses. f, The number of non-silent point mutations shared by each number of MCF7 strains. The 10 naturally occurring connectivity map strains were averaged and considered as a single sample. g, The correlation between proliferation rate (shown as doubling time) and the number of non-silent protein-coding mutations, across naturally occurring MCF7 strains (n = 10). Spearman's ρ and P values indicate the strength and significance of the correlation, respectively. The 10 naturally occurring CMap strains were averaged and considered as a single sample. h, The correlation between proliferation rate (shown as doubling time) and the fraction of subclonal mutations, across naturally occurring MCF7 strains (n = 10). Spearman's ρ and P values indicate the strength and significance of the correlation, respectively. The 10 naturally occurring CMap strains were averaged and considered as a single sample. i, The number of differentially expressed genes identified in all possible pairwise comparisons of MCF7 strains, using a twofold change cutoff. The 10 naturally occurring CMap strains were averaged and considered as a single sample. j, Pie charts of the classification of the screened compounds based on their differential activity. The response to each active compound was defined as consistent if viability change was <−50% for all strains, variable if viability change was <−50% for some strains and >−20% for other strains, or intermediate if viability change was in between these values. Classification was performed using a one-strain or a two-strain resistance threshold (top and bottom charts, respectively). The 10 naturally occurring CMap strains were averaged and considered as a single sample. k, The dose-response curves for ten compounds are shown. For each compound, eight concentrations were tested in each strain. Two sensitive strains and two insensitive strains are plotted. Each data point represents the mean of two replicates. Nutlin-3, a compound that had no toxicity against any of the strains in the primary screen, was included as negative control. Romidepsin, a compound that killed all strains very efficiently in the primary screen was included as positive control and turned out to be differentially active at lower concentrations. l, The Pearson's correlation of the two compound screen replicates across the MCF7 strains. m, Strains more sensitive to proteasome inhibitors exhibit higher proteasome activity. The chymotrypsin-like activity of the proteasome was measured in three sensitive and three insensitive strains. Data are mean ± s.d., onetailed t-test, n = 4 replicate wells. n, Western blots of the relative protein expression levels of the proteasome 19S complex members PSMC2 and PSMD1 in three sensitive and three insensitive strains. The expression of α-tubulin was used for normalization. The experiment was repeated once, with n = 3 strains per group. For gel source data, see Supplementary Fig. 1 . o, Quantification of the relative expression of PSMC2 and PSMD1. Data are mean ± s.d., one-tailed t-test, n = 3 strains per group. p, Upregulation of the KEGG cell cycle signature in strains sensitive to the cell cycle inhibitor CDK/CRK inhibitor (n = 3) compared to insensitive strains (n = 12). q, Upregulation of mTOR signalling in strains sensitive to the PI3K inhibitor PP-121 (n = 11) compared to insensitive strains (n = 5). r, Downregulation of the genes that are downregulated when ALK is knocked down in strains sensitive to the ALK inhibitor TAE-684 (n = 4) compared to insensitive strains (n = 15). s, Upregulation of IL-6-JAK-STAT3 signalling in strains sensitive to the STAT inhibitor nifuroxazide (n = 9) compared to insensitive strains (n = 6). t, Upregulation of the genes that are upregulated when AKT is overexpressed in strains sensitive to the AKT inhibitor triciribine (n = 2) compared to insensitive strains (n = 8). u, Upregulation of hypoxia signalling in strains sensitive to the HSP inhibitor 17-AAG (n = 3) compared to insensitive strains (n = 15). v, Downregulation of xenobiotic metabolism signatures in strains M and Q (n = 2), which exhibited an increased resistance to most compounds compared to the other strains (n = 25). w, Upregulation of the early and late oestrogen response signatures, in strains most sensitive to the ER inhibitor tamoxifen (n = 5) compared to the least sensitive strains (n = 5).
x, Sensitivity to oestrogen depletion and to tamoxifen is associated with the copy number status of ESR1. Heat maps represent the relative viability in oestrogen-depleted medium (top) and in response to tamoxifen (at 16.6 μM; bottom).
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data analysis
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